Logo image of VCEL

VERICEL CORP (VCEL) Stock Fundamental Analysis

USA - NASDAQ:VCEL - US92346J1088 - Common Stock

30.23 USD
+0.39 (+1.31%)
Last: 9/26/2025, 8:00:02 PM
30.23 USD
0 (0%)
After Hours: 9/26/2025, 8:00:02 PM
Fundamental Rating

5

Overall VCEL gets a fundamental rating of 5 out of 10. We evaluated VCEL against 538 industry peers in the Biotechnology industry. While VCEL has a great profitability rating, there are some minor concerns on its financial health. VCEL is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

VCEL had positive earnings in the past year.
VCEL had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VCEL reported negative net income in multiple years.
Each year in the past 5 years VCEL had a positive operating cash flow.
VCEL Yearly Net Income VS EBIT VS OCF VS FCFVCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

The Return On Assets of VCEL (1.63%) is better than 90.33% of its industry peers.
Looking at the Return On Equity, with a value of 2.32%, VCEL belongs to the top of the industry, outperforming 91.64% of the companies in the same industry.
VCEL has a Return On Invested Capital of 0.24%. This is amongst the best in the industry. VCEL outperforms 89.78% of its industry peers.
Industry RankSector Rank
ROA 1.63%
ROE 2.32%
ROIC 0.24%
ROA(3y)-1.54%
ROA(5y)-1.26%
ROE(3y)-2.18%
ROE(5y)-1.76%
ROIC(3y)N/A
ROIC(5y)N/A
VCEL Yearly ROA, ROE, ROICVCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

With an excellent Profit Margin value of 2.85%, VCEL belongs to the best of the industry, outperforming 90.52% of the companies in the same industry.
VCEL's Operating Margin of 0.48% is amongst the best of the industry. VCEL outperforms 89.78% of its industry peers.
VCEL has a better Gross Margin (73.47%) than 82.34% of its industry peers.
In the last couple of years the Gross Margin of VCEL has remained more or less at the same level.
Industry RankSector Rank
OM 0.48%
PM (TTM) 2.85%
GM 73.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y1.27%
VCEL Yearly Profit, Operating, Gross MarginsVCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VCEL is destroying value.
Compared to 1 year ago, VCEL has more shares outstanding
Compared to 5 years ago, VCEL has more shares outstanding
VCEL has a worse debt/assets ratio than last year.
VCEL Yearly Shares OutstandingVCEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
VCEL Yearly Total Debt VS Total AssetsVCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 6.75 indicates that VCEL is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.75, VCEL is in the better half of the industry, outperforming 79.93% of the companies in the same industry.
VCEL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
VCEL has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: VCEL outperforms 45.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.75
ROIC/WACC0.02
WACC9.92%
VCEL Yearly LT Debt VS Equity VS FCFVCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

VCEL has a Current Ratio of 4.97. This indicates that VCEL is financially healthy and has no problem in meeting its short term obligations.
VCEL has a Current ratio (4.97) which is comparable to the rest of the industry.
A Quick Ratio of 4.56 indicates that VCEL has no problem at all paying its short term obligations.
VCEL has a Quick ratio (4.56) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.97
Quick Ratio 4.56
VCEL Yearly Current Assets VS Current LiabilitesVCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 864691128455134976.00% over the past year.
The Earnings Per Share has been growing slightly by 3.71% on average over the past years.
VCEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.13%.
VCEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.01% yearly.
EPS 1Y (TTM)864691128455134800%
EPS 3YN/A
EPS 5Y3.71%
EPS Q2Q%90%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y14.95%
Revenue growth 5Y15.01%
Sales Q2Q%20.09%

3.2 Future

VCEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.77% yearly.
The Revenue is expected to grow by 22.42% on average over the next years. This is a very strong growth
EPS Next Y24.67%
EPS Next 2Y88.52%
EPS Next 3Y80.79%
EPS Next 5Y49.77%
Revenue Next Year15.49%
Revenue Next 2Y18.93%
Revenue Next 3Y20.19%
Revenue Next 5Y22.42%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VCEL Yearly Revenue VS EstimatesVCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
VCEL Yearly EPS VS EstimatesVCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

VCEL is valuated quite expensively with a Price/Earnings ratio of 251.92.
90.15% of the companies in the same industry are more expensive than VCEL, based on the Price/Earnings ratio.
VCEL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.32.
Based on the Price/Forward Earnings ratio of 47.26, the valuation of VCEL can be described as expensive.
89.41% of the companies in the same industry are more expensive than VCEL, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.89, VCEL is valued quite expensively.
Industry RankSector Rank
PE 251.92
Fwd PE 47.26
VCEL Price Earnings VS Forward Price EarningsVCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200 250

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, VCEL is valued cheaply inside the industry as 89.59% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 142.43
VCEL Per share dataVCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VCEL does not grow enough to justify the current Price/Earnings ratio.
VCEL has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as VCEL's earnings are expected to grow with 80.79% in the coming years.
PEG (NY)10.21
PEG (5Y)67.83
EPS Next 2Y88.52%
EPS Next 3Y80.79%

More info and screens

0

5. Dividend

5.1 Amount

VCEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERICEL CORP

NASDAQ:VCEL (9/26/2025, 8:00:02 PM)

After market: 30.23 0 (0%)

30.23

+0.39 (+1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners111.28%
Inst Owner Change0.45%
Ins Owners1.04%
Ins Owner Change2.25%
Market Cap1.53B
Analysts87.14
Price Target54.06 (78.83%)
Short Float %11.02%
Short Ratio8.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.99%
Min EPS beat(2)-78.61%
Max EPS beat(2)68.63%
EPS beat(4)3
Avg EPS beat(4)16.25%
Min EPS beat(4)-78.61%
Max EPS beat(4)68.63%
EPS beat(8)6
Avg EPS beat(8)20.38%
EPS beat(12)8
Avg EPS beat(12)32.28%
EPS beat(16)8
Avg EPS beat(16)-1.68%
Revenue beat(2)0
Avg Revenue beat(2)-4.04%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)-3.86%
Revenue beat(4)1
Avg Revenue beat(4)-2.16%
Min Revenue beat(4)-4.23%
Max Revenue beat(4)2.84%
Revenue beat(8)2
Avg Revenue beat(8)-1.28%
Revenue beat(12)4
Avg Revenue beat(12)-0.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.44%
PT rev (1m)-1.62%
PT rev (3m)-10.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-112.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.8%
Valuation
Industry RankSector Rank
PE 251.92
Fwd PE 47.26
P/S 6.12
P/FCF N/A
P/OCF 32.29
P/B 4.97
P/tB 5.07
EV/EBITDA 142.43
EPS(TTM)0.12
EY0.4%
EPS(NY)0.64
Fwd EY2.12%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)0.94
OCFY3.1%
SpS4.94
BVpS6.08
TBVpS5.96
PEG (NY)10.21
PEG (5Y)67.83
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 2.32%
ROCE 0.3%
ROIC 0.24%
ROICexc 0.34%
ROICexgc 0.35%
OM 0.48%
PM (TTM) 2.85%
GM 73.47%
FCFM N/A
ROA(3y)-1.54%
ROA(5y)-1.26%
ROE(3y)-2.18%
ROE(5y)-1.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y1.27%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.17
Cap/Depr 667.96%
Cap/Sales 22.3%
Interest Coverage 250
Cash Conversion 496.85%
Profit Quality N/A
Current Ratio 4.97
Quick Ratio 4.56
Altman-Z 6.75
F-Score7
WACC9.92%
ROIC/WACC0.02
Cap/Depr(3y)649.08%
Cap/Depr(5y)464.88%
Cap/Sales(3y)15.17%
Cap/Sales(5y)10.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)864691128455134800%
EPS 3YN/A
EPS 5Y3.71%
EPS Q2Q%90%
EPS Next Y24.67%
EPS Next 2Y88.52%
EPS Next 3Y80.79%
EPS Next 5Y49.77%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y14.95%
Revenue growth 5Y15.01%
Sales Q2Q%20.09%
Revenue Next Year15.49%
Revenue Next 2Y18.93%
Revenue Next 3Y20.19%
Revenue Next 5Y22.42%
EBIT growth 1Y131.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2048.47%
EBIT Next 3Y242.91%
EBIT Next 5Y173.2%
FCF growth 1Y-161.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.11%
OCF growth 3Y26.05%
OCF growth 5YN/A